Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2792939 | 0.93 | MAOB (0.52) | MAOBLTA4HNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2797735 | 0.84 | MAOB (0.55) | MAOBSMN1; SMN2HTR2ATAAR1 | |
| SCHEMBL8381114 | 0.81 | LTA4H (0.50) | MAOBLTA4HNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2794517 | 0.79 | LTA4H (0.37) | MAOBLTA4HSMN1; SMN2 | |
| SCHEMBL13886620 | 0.78 | HTR2A (0.68) | LTA4HNPC1RAB9ASMN1; SMN2HTR2A | |
| SCHEMBL1586637 | 0.77 | HTR2A (0.66) | MAOBLTA4HNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13886600 | 0.76 | NPC1 (0.76) | LTA4HNPC1RAB9ASMN1; SMN2HTR2A | |
| SCHEMBL450741 | 0.75 | HTR2A (0.63) | MAOBLTA4HNPC1RAB9ASMN1; SMN2 | |
| Bromide SCHEMBL9512696 | 0.75 | NPC1 (0.73) | LTA4HNPC1RAB9ASMN1; SMN2HTR2A | |
| Hydrochloric Acid SCHEMBL4450595 | 0.75 | NPC1 (0.73) | MAOBLTA4HNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150210643-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | LABORATORIOS ALMIRALL, S.A. | 2015-07-30 | — | — | US | disclosed |
| EP-2057122-B1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE 2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2010-09-01 | — | — | EP | disclosed |
| US-20100168161-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-07-01 | — | — | US | disclosed |
| EP-2057122-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE 2 ADRENERGIC RECEPTOR | Laboratorios Almirall, S.A. (ES) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008046598-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE β2 ADRENERGIC RECEPTOR | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168161-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ADRB2, ADRB1, ADRA2C | MAOB 514/4885LTA4H 1144/4885NPC1 2148/4885 |
| US-20150210643-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ADRB2, ADRB1, ADRA2C | MAOB 514/4885LTA4H 1144/4885NPC1 2148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.